Agenus (AGEN) Cash from Financing Activities (2010 - 2026)
Agenus (AGEN) posted quarterly Cash from Financing Activities of -$993000.0 for Q1 2026, down 127.63% year-over-year from $3.6 million in Q1 2025, and down 106.46% quarter-over-quarter from $15.4 million in Q4 2025.
Analysis
Agenus (AGEN) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Agenus' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$993000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 127.63% year-over-year to -$993000.0; the TTM figure through Mar 2026 stood at $32.0 million (down 71.32% YoY), while the FY2025 annual figure was $36.6 million, down 70.21% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$993000.0, down from $15.4 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $79.1 million in Q2 2024, with the low at -$993000.0 in Q1 2026.
- The 5-year median for Cash from Financing Activities is $16.0 million (2022), against an average of $22.0 million.
- The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities jumped 250.73% in 2023, then sank 127.63% in 2026.
- Agenus' Cash from Financing Activities stood at $23.8 million in 2022, then plunged by 69.23% to $7.3 million in 2023, then surged by 233.15% to $24.4 million in 2024, then sank by 36.91% to $15.4 million in 2025, then slumped by 106.46% to -$993000.0 in 2026.
- Business Quant data shows AGEN's Cash from Financing Activities at -$993000.0 in Q1 2026, $15.4 million in Q4 2025, and $6.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Agenus | 344.35 Mn | 344.35 Mn | 34.52 Mn | 14.68 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 14.68 Mn |
| Mar 31, 2026 | -993,000.00 |
| Dec 31, 2025 | 15.37 Mn |
| Sep 30, 2025 | 6.68 Mn |
| Jun 30, 2025 | 10.94 Mn |
| Mar 31, 2025 | 3.59 Mn |
| Dec 31, 2024 | 24.37 Mn |
| Sep 30, 2024 | 4.56 Mn |
| Jun 30, 2024 | 79.08 Mn |
| Mar 31, 2024 | 14.83 Mn |
| Dec 31, 2023 | 7.32 Mn |
| Sep 30, 2023 | 18.04 Mn |
| Jun 30, 2023 | 38.26 Mn |
| Mar 31, 2023 | 56.25 Mn |
| Dec 31, 2022 | 23.77 Mn |
| Sep 30, 2022 | 28.22 Mn |
| Jun 30, 2022 | 27.80 Mn |
| Mar 31, 2022 | 16.04 Mn |
| Dec 31, 2021 | 71.61 Mn |
| Sep 30, 2021 | 78.91 Mn |